Stem cell-based therapy for Parkinson's disease.
(2005) In Annals of Medicine 37(7). p.487-498- Abstract
- Motor dysfunctions in Parkinson's disease are considered to be primarily due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta. Pharmacological therapies based on the principle of dopamine replacement are extremely valuable, but suffer from two main drawbacks: troubling side effects (e.g. dyskinesia) and loss of efficacy with disease progression. Transplantation of embryonic dopaminergic neurons has emerged as a therapeutic alternative. Enthusiasm following the success of the initial open-label trials has been dampened by the negative outcome of double-blind placebo controlled trials. Additionally, the emergence of graft-related dyskinesia indicates that the experimental grafting procedure requires further... (More)
- Motor dysfunctions in Parkinson's disease are considered to be primarily due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta. Pharmacological therapies based on the principle of dopamine replacement are extremely valuable, but suffer from two main drawbacks: troubling side effects (e.g. dyskinesia) and loss of efficacy with disease progression. Transplantation of embryonic dopaminergic neurons has emerged as a therapeutic alternative. Enthusiasm following the success of the initial open-label trials has been dampened by the negative outcome of double-blind placebo controlled trials. Additionally, the emergence of graft-related dyskinesia indicates that the experimental grafting procedure requires further refinement before it can be developed into a therapy. Shortage of embryonic donor tissue limits large-scale clinical transplantation trials. We review three of the most attractive tissue sources of dopaminergic neurons for cell replacement therapy: human embryonic ventral mesencephalic tissue, embryonic and adult multipotent region-specific stem cells and embryonic stem cells. Recent developments in embryonic stem cell research and on their implications for a future transplantation therapy in Parkinson's disease are described. Finally, we discuss how human embryonic stem cells can be differentiated into dopaminergic neurons, and issues such as the numbers of dopaminergic neurons required for success and the risk for teratoma formation after implantation. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/148043
- author
- Correia, Sofia LU ; Anisimov, Sergey LU ; Li, Jia-Yi LU and Brundin, Patrik LU
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Dopaminergic neurons, neural transplantation, Parkinson's disease, stem cells
- in
- Annals of Medicine
- volume
- 37
- issue
- 7
- pages
- 487 - 498
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:16278162
- wos:000233730800004
- scopus:28144451899
- ISSN
- 1365-2060
- DOI
- 10.1080/07853890500327967
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041)
- id
- ae4f4e08-c5f9-4649-bd06-ee5289e87c4e (old id 148043)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16278162&dopt=Abstract
- date added to LUP
- 2016-04-01 11:36:26
- date last changed
- 2022-04-12 22:29:27
@article{ae4f4e08-c5f9-4649-bd06-ee5289e87c4e,
abstract = {{Motor dysfunctions in Parkinson's disease are considered to be primarily due to the degeneration of dopaminergic neurons in the substantia nigra pars compacta. Pharmacological therapies based on the principle of dopamine replacement are extremely valuable, but suffer from two main drawbacks: troubling side effects (e.g. dyskinesia) and loss of efficacy with disease progression. Transplantation of embryonic dopaminergic neurons has emerged as a therapeutic alternative. Enthusiasm following the success of the initial open-label trials has been dampened by the negative outcome of double-blind placebo controlled trials. Additionally, the emergence of graft-related dyskinesia indicates that the experimental grafting procedure requires further refinement before it can be developed into a therapy. Shortage of embryonic donor tissue limits large-scale clinical transplantation trials. We review three of the most attractive tissue sources of dopaminergic neurons for cell replacement therapy: human embryonic ventral mesencephalic tissue, embryonic and adult multipotent region-specific stem cells and embryonic stem cells. Recent developments in embryonic stem cell research and on their implications for a future transplantation therapy in Parkinson's disease are described. Finally, we discuss how human embryonic stem cells can be differentiated into dopaminergic neurons, and issues such as the numbers of dopaminergic neurons required for success and the risk for teratoma formation after implantation.}},
author = {{Correia, Sofia and Anisimov, Sergey and Li, Jia-Yi and Brundin, Patrik}},
issn = {{1365-2060}},
keywords = {{Dopaminergic neurons; neural transplantation; Parkinson's disease; stem cells}},
language = {{eng}},
number = {{7}},
pages = {{487--498}},
publisher = {{Taylor & Francis}},
series = {{Annals of Medicine}},
title = {{Stem cell-based therapy for Parkinson's disease.}},
url = {{http://dx.doi.org/10.1080/07853890500327967}},
doi = {{10.1080/07853890500327967}},
volume = {{37}},
year = {{2005}},
}